HepCBC Mission Statement
HepCBC is a non-profit organization run by and for people infected and affected by hepatitis C. Our mission is to provide education, prevention and support to those living with HCV.
Hot Off The Press!
By KATIE THOMAS SEPT. 27, 2016 Reprinted without permission as a public service Credit Mike Bradley for The New York Times When Cyndi Zagieboylo, chief executive of the National Multiple Sclerosis Society, started organizing an effort to raise the issue of drug pricing with insurers and pharmaceuticals, she quickly met resistance. Public anger over the cost of drugs has burned hot for a year, coursing through social media, popping up on
From October 1, GPs around New Zealand will start prescribing life-changing medication to many of the 50,000 people living with hepatitis C in New Zealand. Viekira Pak, a breakthrough treatment which was previously out of reach to ordinary New Zealanders, is now fully funded by Pharmac. The drug treats people with hepatitis C genotype 1 who have compensated disease, which is more than half of all New Zealanders living with the virus. Renowned liver spe
HepCBC Hepatitis C Education-Prevention as well as Pacific Hep C Network in BC and CAPAHC in Quebec were all turned down yesterday for all Public Health Agency of Canada (PHAC) funding - not sure yet about HepNS. These are the largest, most active organizations in Canada who actually deal directly with REAL PEOPLE who are MONO-infected with hepatitis C. Yes, the emperor is naked, Daryl Luster (see letter below), you're so right. We've never gotten go
Friday, September-30-16 HCV Infection Increases Extrahepatic Mortality This month the eViralHepatitis Review from Johns Hopkins University devoted a whole issue to Extrahepatic Manifestations of Hepatitis C: Screening and Management. Because HCV is typically considered a primary infection of the liver, its eradication is thought to result in health benefits primarily from improved hepatic outcomes, with most literature supporting reductions in the...
Because HCV is typically considered a primary infection of the liver, its eradication is thought to result in health benefits primarily from improved hepatic outcomes, with most literature supporting reductions in the development of cirrhosis and its complications.1 The paradigm that HCV is a liver disease and mortality is driven by liver-related complications has guided clinical decision-making, and more recently, reimbursement criteria.1,2 However, HCV i